New Amsterdam Sciences, Inc

New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911B is the company's lead compound, and is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, wound healing and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial market and government markets, with exceptional candidates for mass-casualty biodefense applications specifically addressing acute radiation sickness (neutropenia), chemical exposure and biological warfare scenarios. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, Harvard School of Medicine, and more. For additional information, please visit www.newamsterdamsciences.com